Agilus Diagnostics, a leading diagnostic service provider and subsidiary of Fortis Healthcare Ltd., has launched the Complete Care Vital Shape test suite—available in Lite, Core and Ultra variants. This structured diagnostic portfolio aims to support smarter weight management, early detection of insulin resistance and long-term monitoring of metabolic health. The launch comes at a time when global attention is rapidly shifting toward GLP-1–based therapies for obesity.
Rising Obesity Burden Highlights Need for Advanced Diagnostics
India continues to record a steep rise in obesity, with nearly one in four women and two in five men now overweight or obese. In urban regions, prevalence has surged to 30–40%, driven by lifestyle changes and dietary patterns. Consequently, the growing disease burden highlights the urgent need for comprehensive diagnostics. These tools support prevention, guide clinical decisions and track long-term metabolic risks.
Overview of the Vital Shape Suite
The Vital Shape panels provide tiered levels of assessment to detect obesity-related and metabolic risks at an early stage.
Vital Shape Lite (72 parameters)
This introductory panel delivers a robust baseline metabolic assessment. It includes BMI, a Comprehensive Metabolic Profile (CMP), eGFR for kidney function, CBC, lipid profile, free thyroid profile, HbA1c, fasting insulin, HOMA-IR for insulin resistance, FIB-4 for liver status, ferritin and iron studies for anemia and Vitamin D and B12 levels.
Vital Shape Core (80 parameters)
The Core panel builds on the Lite suite by adding hsCRP for cardiac inflammation and additional. It is also nutritional and metabolic markers, offering deeper insights into metabolic derangements.
Vital Shape Ultra (86 parameters)
As one of India’s most expansive obesity-focused diagnostic suites, the Ultra panel incorporates leptin and adiponectin for metabolic signalling, amylase and lipase for pancreatitis risk and PTH with calcium for endocrine and bone health. This panel provides advanced insights into fatty liver, chronic inflammation and hormonal contributors to metabolic dysfunction.
Leadership Highlights the Clinical Relevance
Dr. Anand K, Managing Director & CEO of Agilus Diagnostics, emphasised the global shift in obesity care and the rising use of GLP-1–based therapies. He noted that diagnostics must evolve alongside clinical practice. “Complete Care Vital Shape empowers clinicians with comprehensive insights into insulin resistance, fatty liver, metabolic syndrome and cardiometabolic disorders,” he said. “These conditions remain silent for years, making early detection essential for preventive and personalised care.”
Dr. Ajay Phadke, Director – Strategic Business Development, added that Agilus has observed a sharp increase in enquiries for structured metabolic assessments. “Complete Care Vital Shape positions Agilus among the select few offering such detailed, clinically oriented panels. As GLP-1 agonist use rises, clinicians require deeper baseline evaluations and continuous monitoring to track metabolic risks. This suite is designed precisely for those needs.”
Supporting the Evolving Landscape of Obesity Care
GLP-1 therapies are gaining global acceptance. Clinicians now emphasise baseline metabolic evaluations and periodic monitoring throughout treatment. Given India’s large population vulnerable to diabetes, cardiovascular disease and fatty liver, standardised diagnostic protocols have become essential.
The press release states that the Complete Care Vital Shape suite has been developed to meet this emerging clinical need. It helps establish baseline metabolic profiles for GLP-1 therapy and supports ongoing monitoring to ensure therapeutic efficacy.